Antibody-Directed Enzyme Prodrug Therapy

Jump to navigation Jump to search

WikiDoc Resources for Antibody-Directed Enzyme Prodrug Therapy

Articles

Most recent articles on Antibody-Directed Enzyme Prodrug Therapy

Most cited articles on Antibody-Directed Enzyme Prodrug Therapy

Review articles on Antibody-Directed Enzyme Prodrug Therapy

Articles on Antibody-Directed Enzyme Prodrug Therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Antibody-Directed Enzyme Prodrug Therapy

Images of Antibody-Directed Enzyme Prodrug Therapy

Photos of Antibody-Directed Enzyme Prodrug Therapy

Podcasts & MP3s on Antibody-Directed Enzyme Prodrug Therapy

Videos on Antibody-Directed Enzyme Prodrug Therapy

Evidence Based Medicine

Cochrane Collaboration on Antibody-Directed Enzyme Prodrug Therapy

Bandolier on Antibody-Directed Enzyme Prodrug Therapy

TRIP on Antibody-Directed Enzyme Prodrug Therapy

Clinical Trials

Ongoing Trials on Antibody-Directed Enzyme Prodrug Therapy at Clinical Trials.gov

Trial results on Antibody-Directed Enzyme Prodrug Therapy

Clinical Trials on Antibody-Directed Enzyme Prodrug Therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Antibody-Directed Enzyme Prodrug Therapy

NICE Guidance on Antibody-Directed Enzyme Prodrug Therapy

NHS PRODIGY Guidance

FDA on Antibody-Directed Enzyme Prodrug Therapy

CDC on Antibody-Directed Enzyme Prodrug Therapy

Books

Books on Antibody-Directed Enzyme Prodrug Therapy

News

Antibody-Directed Enzyme Prodrug Therapy in the news

Be alerted to news on Antibody-Directed Enzyme Prodrug Therapy

News trends on Antibody-Directed Enzyme Prodrug Therapy

Commentary

Blogs on Antibody-Directed Enzyme Prodrug Therapy

Definitions

Definitions of Antibody-Directed Enzyme Prodrug Therapy

Patient Resources / Community

Patient resources on Antibody-Directed Enzyme Prodrug Therapy

Discussion groups on Antibody-Directed Enzyme Prodrug Therapy

Patient Handouts on Antibody-Directed Enzyme Prodrug Therapy

Directions to Hospitals Treating Antibody-Directed Enzyme Prodrug Therapy

Risk calculators and risk factors for Antibody-Directed Enzyme Prodrug Therapy

Healthcare Provider Resources

Symptoms of Antibody-Directed Enzyme Prodrug Therapy

Causes & Risk Factors for Antibody-Directed Enzyme Prodrug Therapy

Diagnostic studies for Antibody-Directed Enzyme Prodrug Therapy

Treatment of Antibody-Directed Enzyme Prodrug Therapy

Continuing Medical Education (CME)

CME Programs on Antibody-Directed Enzyme Prodrug Therapy

International

Antibody-Directed Enzyme Prodrug Therapy en Espanol

Antibody-Directed Enzyme Prodrug Therapy en Francais

Business

Antibody-Directed Enzyme Prodrug Therapy in the Marketplace

Patents on Antibody-Directed Enzyme Prodrug Therapy

Experimental / Informatics

List of terms related to Antibody-Directed Enzyme Prodrug Therapy


Overview

ADEPT (Antibody-directed enzyme prodrug therapy)[1] is a strategy to overcome the problems of lack of tumor selectivity. An antibody designed/developed against a tumor antigen is linked to an enzyme and injected to the blood, resulting in selective binding of the enzyme in the tumor. When the discrimination between tumor and normal tissue enzyme levels is sufficient, a prodrug is administrated into the blood circultion, which is converted to an active cytotoxic drug by the enzyme, only within the tumor. Selectivity is achieved by the tumor specificity of the antibody and by delaying prodrug administration until there is a large differential between tumor and normal tissue enzyme levels.

ADEPT has shown antitumor activity in animal tumor models of human choriocarcinoma and colonic and breast carcinoma.

ADEPT history

The first pilot-scale clinical trial of ADEPT was carried out at Charing Cross Hospital, London, using an anti-CEA F(ab′)2 antibody conjugated to the bacterial enzyme carboxypeptidase G2 (CPG2)[2].

The antibody used in the first ADEPT clinical trial was of murine origin and the enzyme was bacterial. Host antibodies to both components of the AEC were present in the blood of all non-immunosuppressed patients by day 10 after AEC infusion [3]. Several patients received cyclosporin since it had been shown in rabbits that this could delay the appearance of host antibodies to soluble proteins [4].

A subsequent, small-scale trial at the Royal Free Hospital, London, used the same agents as in the Charing Cross Hospital trial but the protocol was modified to provide additional pharmacokinetic data and most patients received only a single course of treatment [5].

Other versions of directed enzyme prodrug therapy (DEPT)

There are several other strategies to use prodrug/enzyme systems for cancer therapy, including gene-directed enzyme prodrug therapy (GDEPT), virus-directed enzyme prodrug therapy (VDEPT), PDEPT (Polymer-Directed Enzyme Prodrug Therapy), LEAPT (Lectin-directed enzyme-activated prodrug therapy)[6][7], and CDEPT[8] (Clostridial-directed enzyme prodrug therapy).

References

  1. Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther. 2006; 6(10): 1421-1431.Template:Entrez Pubmed
  2. KD Bagshawe, SK Sharma, CJ Springer and P Antoniw, Antibody directed enzyme prodrug therapy (ADEPT): a pilot scale clinical trial. Tumor Targeting 1 (1995) 17–29.
  3. KD Bagshawe and SK Sharma, Cyclosporin delays host immune response to antibody enzyme conjugate in ADEPT. Transplant Proc 28 (1996), 3156–3158. Template:Entrez Pubmed
  4. JA Ledermann, RHJ Begent and KD Bagshawe, Cyclosporin A prevents the anti murine antibody response to a monoclonal antibody in rabbits. Br J Cancer 58 (1988), 562–566.
  5. KD Bagshawe and M Napier, Early clinical studies with ADEPT. In: RG Melton and RJ Knox Editors, Enzyme-Prodrug Strategies for Cancer Therapy Kluwer Academic, London (1999), 199–207.
  6. Silva AT, Chung MC, Castro LF, Guido RV, Ferreira EI. Advances in prodrug design. Mini Rev Med Chem. 5 (2005) 893-914.Template:Entrez Pubmed
  7. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 7 (2001) 3314-24.Template:Entrez Pubmed
  8. Minton NP. Clostridia in cancer therapy. Nat Rev Microbiol. 2003;1:237–42.Template:Entrez Pubmed


Template:WikiDoc Sources